Name,Category,Begin Date,End Date,Note
Incidental Finding on CT,Milestones,2021-08-01,,CT for kidney stones found liver mass
MRI Liver,Biomarker Assess,2021-08-10,,2.8cm intrahepatic lesion
Liver Biopsy,Biomarker Assess,2021-08-18,,Cholangiocarcinoma confirmed
Staging Workup,Biomarker Assess,2021-08-25,,No metastatic disease
CA 19-9,Biomarker Assess,2021-08-25,,145 U/mL
Right Hepatectomy,Milestones,2021-09-15,,R0 resection achieved
Pathology,Biomarker Assess,2021-09-22,,T1N0 favorable pathology
Adjuvant Capecitabine,Line 1 treatment,2021-10-20,2022-04-20,6 months adjuvant
6-Month Surveillance,Milestones,2022-04-20,,NED
12-Month Surveillance,Milestones,2022-09-15,,NED continued
18-Month Surveillance,Milestones,2023-03-15,,NED
24-Month Rising CA 19-9,Biomarker Assess,2023-09-15,,Increased to 85 U/mL
CT Shows Recurrence,Biomarker Assess,2023-09-25,,Peritoneal nodules detected
Peritoneal Recurrence,Complications,2023-09-25,,Disease recurrence 2 years post-op
Molecular Testing Repeated,Biomarker Assess,2023-10-01,,FGFR2 fusion now detected
GemCis Durvalumab,Line 2 treatment,2023-10-15,2024-04-15,First-line for recurrence
Restaging Stable,Biomarker Assess,2024-01-15,,Stable disease
Pemigatinib Planned,Milestones,2024-04-20,,FGFR inhibitor after chemo
